WHO: HOMOSEXUALITY-RELATED ‘DISORDERS’ SHOULD BE DROPPED
A World Health Organisation (WHO) working group has called for the scrapping of so-called “homosexuality-related psychological disorders”.
South Africa faces HIV funding test with shift in PEPFAR money
With PEPFAR planning to shift about $100 million in HIV funding from South Africa to poorer countries, the New York Times reports, the country will face stern challenges in maintaining its AIDS effort.
STUDY: Tivicay Surpresses HIV Even in Those Who are Drug Resistant
Tivicay, the recently approved HIV integrase inhibitor — a class of antiretroviral drug that is designed to block a virus from entering the DNA of a host cell — demonstrated high rates of viral suppression in a recent study. Significantly, Tivicay is also proven effective for people who are resistant to HIV antiretroviral drugs, according to NAM.
2014 Global Men’s Health and Rights Survey
Be heard! Share your experiences and be counted in this global survey on the health and human rights of gay men and other men who have sex with men (MSM)!
Forced mutations doom HIV
Fifteen years ago, MIT professor John Essigmann and colleagues from the University of Washington had a novel idea for an HIV drug. They thought if they could induce the virus to mutate uncontrollably, they could force it to weaken and eventually die out — a strategy that our immune system uses against many viruses.
No Link Between Efavirenz and Neurocognitive Impairment in Italian Study
The widely used antiretroviral drug efavirenz was not linked with neurocognitive impairment in a study reported this week at AIDS 2014. Efavirenz (Sustiva, also part of the popular Atripla combo pill) has been associated with a variety of neuropsychiatric symptoms ranging from vivid dreams to depression, but whether the drug contributes to neurocognitive impairment (NCI) has been debated.
A proof of concept for an HIV cure exists. Now even our setbacks are useful
The Mississippi baby, in remission for over two years, recently experienced HIV rebound. This low – if it can be called that – shouldn’t dampen our hopes for a cure
More men say “yes” to PrEP in a post-trial access study
Data presented today at the International AIDS Conference in Melbourne and published simultaneously in the Lancet provides the first clear evidence for who wants PrEP—and how they use it outside of the United States.
PrEP Works Despite Missed Doses, Although Daily Use Is Advised
No one who took Truvada PrEP at least four times per week acquired HIV in the iPrEx Open Label Extension (iPrEx OLE) demonstration project, according to data presented today at the AIDS 2014 conference in Melbourne. These new data support PrEP as a valuable HIV prevention option even when adherence may be less than 100%.
“Adherence has to be good, not great,” said iPrEx protocol chair Robert Grant, MD, MPH, of the Gladstone Institutes, the University of California at San Francisco, and San Francisco AIDS Foundation, in his late-breaker presentation of the study results.
Researchers Find New Way to Kick Out HIV From Infected Cells
The technique addresses the problem of hidden reservoirs of HIV in the body, and could herald a new way of battling the viral infection